Search company, investor...
Centaur Pharmaceuticals company logo

Centaur Pharmaceuticals

Founded Year



Acquired | Acquired

Total Raised




About Centaur Pharmaceuticals

Centaur Pharmaceuticals developed a class of small molecule pharmaceutical compounds for the treatment of neurodegenerative and inflammatory diseases such as acute stroke, dementia, rheumatoid arthritis, myocardial ischemia and Parkinson's disease. Renovis is a biopharmaceutical company with a primary focus on the discovery, development and commercialization of drugs to treat neurological diseases and disorders. Renovis acquired Centaur Pharmaceuticals, Inc. in December 2002.

Headquarters Location

1220 Memorex Drive Opp. Grand Hyatt, Vakola

Santa Clara, California, 95050,

United States


Missing: Centaur Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Centaur Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Centaur Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Centaur Pharmaceuticals is included in 1 Expert Collection, including Diabetes.



1,899 items

Centaur Pharmaceuticals Patents

Centaur Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Sedatives, Hypnotics, Barbiturates, Carbamates, Lactams


Application Date


Grant Date



Related Topics

Sedatives, Hypnotics, Barbiturates, Carbamates, Lactams



Latest Centaur Pharmaceuticals News

Centaur Pharmaceuticals clears USFDA audit of Pune plant

Jun 11, 2019

Last Updated : Jun 11, 2019 06:30 PM IST | Source: Centaur Pharmaceuticals clears USFDA audit of Pune plant The company received No Action Indicated (NAI) compliance status with zero 483 observations from the USFDA which signifies compliance and conformance to applicable cGMP regulations Representative image Centaur Pharmaceuticals on June 11 said its Pune finished dosage facility had completed USFDA audit with zero Form 483 observations. The company received a No Action Indicated (NAI) compliance status with zero 483 observations from the USFDA which signifies compliance and conformance to applicable cGMP regulations The successful audit will allow Centaur to expand in US market. “The conclusions of the inspection are reported as No Action Indicated (NAI) which is vindication of Centaur’s efforts over the past 40 years in ensuring quality and maintaining international standards across the pharmaceutical value chain in API, formulations, clinical research and contract manufacturing” said Jayashing Sawant, President- Technical, Centaur Pharmaceuticals. Centaur is also India’s largest and the world’s third largest manufacturer of psychotropic active pharmaceutical ingredients (APIs) . Centaur’s API (Active Pharmaceuticals Ingredients) formulations plant situated in Ambernath, Maharashtra is also an US FDA approved plant. In addition, Centaur Pharmaceuticals also has two formulations facilities in Goa which are WHO-GMP approved. Centaur is a $100 million company by sales with exports to 110 countries. First Published on Jun 11, 2019 06:29 pm

Centaur Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Centaur Pharmaceuticals founded?

    Centaur Pharmaceuticals was founded in 1992.

  • Where is Centaur Pharmaceuticals's headquarters?

    Centaur Pharmaceuticals's headquarters is located at 1220 Memorex Drive, Santa Clara.

  • What is Centaur Pharmaceuticals's latest funding round?

    Centaur Pharmaceuticals's latest funding round is Acquired.

  • How much did Centaur Pharmaceuticals raise?

    Centaur Pharmaceuticals raised a total of $55.82M.

  • Who are the investors of Centaur Pharmaceuticals?

    Investors of Centaur Pharmaceuticals include Cycad Group, SIDBI Venture and SME Growth Fund.

  • Who are Centaur Pharmaceuticals's competitors?

    Competitors of Centaur Pharmaceuticals include ChemoCentryx, Oligomerix, Biocytogen, Sound Pharmaceuticals, Titan Pharmaceuticals, Longevica, Panacea Pharmaceuticals, Mutabilis, Achillion Pharmaceuticals, Array Biopharma and 49 more.

Compare Centaur Pharmaceuticals to Competitors

BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

Inflazyme Pharmaceuticals

Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.

Bikam Pharmaceuticals

BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.

Affectis Pharmaceuticals

Affectis Pharmaceuticals, fka neuronova, is a biopharmaceutical company developing drugs for the treatment of psychiatric and inflammatory disorders.

Oligomerix Logo

Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.

Need Pharma

NeED Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of anti-infective drugs for the treatment of serious and neglected infectious diseases, where a large unmet medical need and market opportunity are clearly present.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.